The NYMX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NYMX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The NYMX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View NYMX Detailed Price Forecast - CNN Money||View NYMX Detailed Summary - Google Finance|
|View NYMX Detailed Summary - Yahoo! Finance||View NYMX Stock Research & Analysis - Zacks.com|
|View NYMX Trends & Analysis - Trade-Ideas||View NYMX Major Holders - Barrons|
|View NYMX Call Transcripts - NASDAQ||View NYMX Breaking News & Analysis - Seeking Alpha|
|View NYMX Annual Report - CompanySpotlight.com||View NYMX OTC Short Report - OTCShortReport.com|
|View NYMX Fundamentals - TradeKing||View NYMX SEC Filings - Bar Chart|
|View Historical Prices for NYMX - The WSJ||View Performance/Total Return for NYMX - Morningstar|
|View the Analyst Estimates for NYMX - MarketWatch||View the Earnings History for NYMX - CNBC|
|View the NYMX Earnings - StockMarketWatch||View NYMX Buy or Sell Recommendations - MacroAxis|
|View the NYMX Bullish Patterns - American Bulls||View NYMX Short Pain Metrics - ShortPainBot.com|
|View NYMX Stock Mentions - StockTwits||View NYMX Stock Mentions - PennyStockTweets|
|View NYMX Stock Mentions - Twitter||View NYMX Investment Forum News - Investor Hub|
|View NYMX Stock Mentions - Yahoo! Message Board||View NYMX Stock Mentions - Seeking Alpha|
|View Insider Transactions for NYMX - SECform4.com||View Insider Transactions for NYMX - Insider Cow|
|View NYMX Major Holdings Summary - CNBC||View Insider Disclosure for NYMX - OTC Markets|
|View Insider Transactions for NYMX - Yahoo! Finance||View Institutional Holdings for NYMX - NASDAQ|
|View NYMX Stock Insight & Charts - FinViz.com||View NYMX Investment Charts - StockCharts.com|
|View NYMX Stock Overview & Charts - BarChart||View NYMX User Generated Charts - Trading View|
Nymox: 3Q Earnings Snapshot
Posted on Tuesday November 13, 2018
The St. Laurent, Quebec-based company said it had a loss of 5 cents per share. The biopharmaceutical company posted revenue of $40,000 in the period. In the final minutes of trading on Tuesday, the company's ...
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
Posted on Thursday October 11, 2018
Regulatory Filings for Fexapotide in BPH: The Company is pleased with the progress its regulatory filings for its lead product, Fexapotide Triflutate, are making for BPH (Benign Prostatic Hyperplasia) both in Europe and the United States. The successful financing earlier this summer has allowed the Company to expand its work with top-end regulatory teams on both continents. Quality Control: The Company has augmented its internal quality control activities with an expanded team and a new office located in Orange County, California.
Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy
Posted on Tuesday October 09, 2018
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer. Paul Averback, CEO of Nymox, said, "These exciting new results confirm and expand the evidence for the beneficial long-term effect of a virtually painless and safe minimal administration of Fexapotide Triflutate to men with low grade localized prostate cancer.
Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
Posted on Wednesday October 03, 2018
HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that after long-term safety assessments of repeated Fexapotide.